Preliminary assessment of of effective doses for patients undergoing hepatic arterial chemoembolization-Reference-Cited by-同舟云学术

Preliminary assessment of of effective doses for patients undergoing hepatic arterial chemoembolization

Published:2021-06-27 Issue:2 Volume:14 Page:83-88
ISSN:1998-426X
Container-title:Radiatsionnaya Gygiena = Radiation Hygiene
language:
Short-container-title:Radiac. gig. (2008)

Author:

Vagidova Z. Ya.¹,Vodovatov A. V.²,Romanovich I. K.¹,Stanzhevsky A. A.³,Polikarpov A. A.³

Affiliation:

1. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being

2. Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being; Saint-Petersburg State Pediatric Medical University

3. A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies

Abstract

The aim of the study was to estimate the patient effective doses from hepatic arterial chemoembolization. The study was based on the parameters of the protocols of liver chemoembolization collected for 67 patients in Angiography department of the «A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies» of the Ministry of Health of the Russian Federation. The parameters were collected using a dedicated questionnaire and exported from digital image files in DICOM format with preliminary anonymization. The simulation of patient exposure was performed using PCXMC 2.0 software. The median values of the patient dose-related quantities (minimum and maximum values) were as follows: total dose–area product – 6.1 Gy×cm2 (3.4-693Gy×cm2), fluoroscopy time – 7.5 min (2.0-28.3 min), effective dose – 11.7 mSv (0.6-132 mSv). For three patients effective doses exceeded 100 mSv. In two cases, total dose-area product exceeded the control values for deterministic effects in the skin. No tissue reactions were identified for the whole patient sample.

Publisher

SPRI of Radiation Hygiene Prof. PV Ramzaev

Subject

Radiology Nuclear Medicine and imaging

Reference12 articles.

1. Chemoembolization T. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. Journal of Vascular and Interventional Radiology: JVIR. 2017; 28: 1210-1223.

2. Polekhin AS, Tarazov PG, Polikarpov AA, Granov DA. Transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma on advanced liver cirrhosis. Vestnik khirurgii imeni I.I. Grekova = Grekov’s Bulletin of Surgery. 2019;178(6): 29-35. (In Russian).

3. Granov DA, Polekhin AS, Tarazov PG, Rutkin IO, Tileubergenov II, Borovik VV. Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alphafetoprotein concentrations. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artificial Organs. 2021;22(4): 52-57. (In Russian) DOI: 10.15825/1995-1191-2020-4-52-57

4. Dauer LT, Thornton R, Boylan DC, Holahan B, Prins R, Quinn B, et al. Organ and effective dose estimates for patients undergoing hepatic arterial embolization for treatment of liver malignancy. Medical Physics. 2011;38(2): 736-742. DOI: 10.1118/1.3533685.

5. Brambilla M, Cannillo B, Guzzardi G, D’Alessio A, Galbiati A, Matheoud R, et al. Conversion factors for effective dose and organ doses with the air kerma area product in patients undergoing percutaneous transhepatic biliary drainage and trans arterial chemoembolization. Physica Medica. 2020;72: 7-15. DOI: 10.1016/j.ejmp.2020.03.003.